5546 Journal of Medicinal Chemistry, 2007, Vol. 50, No. 23
Letters
C.; De Francesco, R.; Gallinari, P.; Steinkuhlre, C.; Di Marco. S.
Crystal structure of a eukaryotic zinc-dependent histone deacetylase,
human HDAC8, complexed with a hydroxamic acid inhibitor. Proc
Natl. Acad. Sci. U.S.A. 2004, 101, 15064-15069. (c) Somoza, J.;
Skene, R.; Katz, B.; Mol, C.; Ho, J.; Jennings, A.; Luong, C.; Arvai,
A.; Buggy, J.; Chi, E.; Tang, J.; Sang, B.; Verner, E.; Wynands, R.;
Leahy, E.; Dougan, D.; Snell, G.; Navre, M.; Knuth, M.; Swanson,
R.; McRee, D.; Tari, L. Structural snapshots of human HDAC8
provide insights into the class I histone deacetylases. Structure 2004,
12, 1325-1334.
structural information. The potential of this novel class of
compounds for treating cell proliferation-related disorders, such
as cancer, is currently being explored. Moreover, the novel
isotype specificity, targeting only HDAC-1 and 2, should be
instrumental in elucidating the mechanism(s) of HDAC involve-
ment in cellular activities and in cancer.
Acknowledgment. The authors would like to thank Dr.
Robert De´ziel for his insightful input into the preparation of
this manuscript.
(11) Wang, D. F.; Wiest, O.; Helquist, P.; Lan-Hargest, H. Y.; Wiech, N.
L. On the function of the 14A long internal cavity of histone
deacetylase-like protein: implications for the design of histone
deacetylase inhibitors. J. Med. Chem. 2004, 47, 3409-3417.
(12) Moradei, O.; Maroun, C.; Paquin, I.; Vaisburg, A. Histone deacetylase
inhibitors: latest developments, trends and prospects. Curr. Med.
Chem. Anticancer Agents 2005, 5, 529-560.
(13) Marks, P. A.; Dokmanovic, M. Histone deacetylase inhibitors:
discovery and development as anticancer agents. Expert Opin. InVest.
Drugs 2005, 14, 1497-14511.
(14) Haggarty, S.; Koeller, K.; Wong, J.; Butcher, R.; Schreiber, S.
Multidimentional chemical genetic analysis of diversity-oriented
synthesis-derived deacetylase inhibitors using cell-based assays.
Chem. Biol. 2003, 10, 383-396.
(15) Moradei, O.; Leit, S.; Zhou, N.; Fre´chette, S.; Paquin, I.; Raeppel,
S.; Gaudette, F.; Bouchain, G.; Woo, S.; Vaisburg, A.; Fournel, M.;
Kalita, A.; Lu, A.; Trachy-Bourget, M.; Pu, T.; Liu, Y.; Li, Z.; Rahil,
J.; MacLeod, A.; Besterman, J.; Delorme, D. Substituted N-(2-
Aminophenyl)-benzamides, (E)-N-(2-Aminophenyl)-acrylamides and
their Analogues: Novel Classes of Histone Deacetylase Inhibitors.
Bioorg. Med. Chem. Lett. 2006, 16, 4048-4052.
(16) Bodner, B.; Jackman, L.; Morgan, R. NMR study of 1:1 complexes
between divalent sulfur and aromatic compounds: a model for
interactions in globular proteins. Biochem. Biophys. Res. Commun.
1980, 94, 807-813.
(17) (a) MethylGene Inc. Inhibitors of histone deacetylase. WO 030704,
2005. (b) MethylGene Inc. Inhibitors of histone deacetylase. WO
030705, 2005.
(18) Seko, S.; Miyake, K.; Kawamura, N. A convenient copper-catalyzed
direct amination of nitroarenes with O-alklyhydroxylamines. J. Chem.
Soc., Perkin Trans. 1 1999, 1437-1444.
(19) Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N.; Saito, A.; Mariko,
Y.; Yamashita, T.; Nakanishi, O. Synthesis and histone deaceylase
inhibitory activity of new benzamide derivatives. J. Med. Chem. 1999,
42, 3001-3003.
Supporting Information Available: Characterization of final
analogues is available. This material is available free of charge via
References
(1) Jenuwein, T.; Allis, C. D. Translating the histone code. Science 2001,
293, 1074-1080.
(2) Timmermann, S.; Lehrmann, H.; Polesskaya, A.; Harel-Bellan, A.
Histone acetylation and disease. Cell. Mol. Life Sci. 2001, 58, 728-
736.
(3) Taunton, J.; Hassig, C. A.; Schreiber, S. L. A mammalian histone
deacetylase related to the yeast transcriptional regulator Rpd3p.
Science 1996, 272, 408-411.
(4) Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of
histone deacetylase inhibitors. Nat. ReV. Drug DiscoVery 2006, 5,
769-784.
(5) Gregoretti, I. V.; Lee, Y.-M.; Goodson, H. V. Molecular evolution
of the histone deacetylase family: functional implications of phy-
logenetic analysis. J. Mol. Biol. 2004, 338, 17-31.
(6) (a) Bertos, N.; Wang, A.; Yang, X. Class II histone deacetylases:
structure, function, and regulation. Biochem. Cell Biolog. 2001, 79,
243-252. (b) Fischle, W.; Kiermer, V.; Dequiedt, F.; Verdin, E. The
emerging role of Class II histone deacetylases. Biochem. Cell Biol.
2001, 79, 337-348.
(7) Grozinger, C.; Schreiber. S. Deacetylase enzymes: biological func-
tions and the use of small-molecule inhibitors. Chem. Biol. 2002, 9,
3-16.
(8) Finnin, M.; Donigian, J.; Cohen, A.; Richon, V.; Rifkind, R.; Marks,
P.; Breslow, R.; Pavietich, N. Strucures of a histone deacetylase
homologue bound to the TSA and SAHA inhibitors. Nature 1999,
401, 188-193.
(9) Nielsen, T.; Hildmann, C.; Dickmanns, A.; Schwienhorst, A.; Ficner,
R. Crystal structure of a bacterial class 2 histone deacetylase
homologue. J. Mol. Biol. 2005, 354, 107-120.
(10) (a) Schuetz, A.; Min, J.; Loppnau, P.; Weigelt, J.; Sundstrom, M.;
Arrowsmith, C.; Edwards, A.; Bochkarev, A., Plotnikov, A. PDB
ID 2PQO and 2PQP. (b) Vannini, A.; Volpari, C.; Filocampo, G.;
Casavola, E.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini,
(20) Chapleur, Y.; Castro, B. Synthetic C-glycosyl nucleosides. A new
approach. J. Chem. Soc., Perkin Trans. 1 1980, 2683-2685.
JM701079H